NASDAQ:CRON Cronos Group Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cronos Group Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.82 -0.06 (-2.08%) (As of 06/30/2022 12:00 AM ET) Add Compare Share Today's Range$2.74▼$2.8650-Day Range$2.59▼$3.5452-Week Range$2.57▼$8.71Volume1.52 million shsAverage Volume2.20 million shsMarket Capitalization$1.07 billionP/E RatioN/ADividend YieldN/APrice Target$4.37 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cronos Group and its competitors with MarketBeat's FREE daily newsletter. Email Address CRON Stock Forecast (MarketRank)Overall MarketRank™1.68 out of 5 starsMedical Sector940th out of 1,433 stocksMedicinals & Botanicals Industry8th out of 23 stocksAnalyst Opinion: 3.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 - 3.0 Analyst's Opinion Consensus RatingCronos Group has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 4 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.37, Cronos Group has a forecasted upside of 55.1% from its current price of $2.82.Amount of Analyst CoverageCronos Group has only been the subject of 3 research reports in the past 90 days. Previous Next 4.1 Community Rank Outperform VotesCronos Group has received 458 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCronos Group has received 288 “underperform” votes. (Add your “underperform” vote.)Community SentimentCronos Group has received 61.39% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote “Outperform” if you believe CRON will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRON will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCronos Group does not currently pay a dividend.Dividend GrowthCronos Group does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cronos Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.52% of the stock of Cronos Group is held by insiders.Percentage Held by InstitutionsOnly 13.40% of the stock of Cronos Group is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Cronos Group are expected to grow in the coming year, from ($0.24) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cronos Group is -31.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cronos Group is -31.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCronos Group has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cronos Group (NASDAQ:CRON)Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. It also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Read More CRON Stock News HeadlinesJune 27, 2022 | finanznachrichten.deFinancialnewsmedia.com: While Cannabis Industry Goes Through Fluctuations, CBD Infused Products Market is Still BoomingJune 23, 2022 | seekingalpha.comAltria's Dividend Is Likely Unsustainable In The Long RunJune 23, 2022 | markets.businessinsider.comWhy Ginkgo Bioworks Shares Are Rising After Announcement With Partner Cronos GroupJune 23, 2022 | incomeinvestors.comAltria Stock: This 8%-Yielder a Sin Stock for the AgesJune 21, 2022 | seekingalpha.comCronos, Ginkgo Bioworks achieve third target milestone for cannabinoidsJune 21, 2022 | americanbankingnews.comAyr Wellness (OTCMKTS:AYRWF) versus Cronos Group (NASDAQ:CRON) Financial ContrastJune 18, 2022 | finance.yahoo.comThose who invested in Cronos Group (TSE:CRON) five years ago are up 107%June 16, 2022 | finanznachrichten.deMicrosmallcap.com: Thailand Becomes First Asian Country to Legalize MarijuanaJune 9, 2022 | reuters.comCANADA STOCKS-Toronto stocks fall as tech, material companies weighJune 9, 2022 | americanbankingnews.comCronos Group (NASDAQ:CRON) Hits New 1-Year Low at $2.82June 8, 2022 | baystreet.caStocks Socked Over Economic ConcernsJune 7, 2022 | baystreet.caStocks Pop by CloseMay 19, 2022 | seekingalpha.comCronos Group Inc. (CRON) CEO Mike Gorenstein presents at 17th Annual BMO Capital Markets Global Farm to Market Conference (Transcript)See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRON CUSIPN/A CIK1656472 Webwww.thecronosgroup.com Phone(416) 504-0004FaxN/AEmployees626Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today6/30/2022Next Earnings (Estimated)8/05/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$4.37 High Stock Price Forecast$6.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+55.1%Consensus RatingHold Rating Score (0-4)2 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.090010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-396.11 million Net Margins-36.04% Pretax Margin-308.35% Return on Equity-15.92% Return on Assets-14.84% Debt Debt-to-Equity Ratio0.01 Current Ratio26.42 Quick Ratio25.50 Sales & Book Value Annual Sales$74.43 million Price / Sales14.31 Cash FlowN/A Price / Cash FlowN/A Book Value$3.56 per share Price / Book0.79Miscellaneous Outstanding Shares377,780,000Free Float356,927,000Market Cap$1.07 billion OptionableOptionable Beta1.66 Cronos Group Frequently Asked Questions Should I buy or sell Cronos Group stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 2 sell ratings, 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Cronos Group stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRON, but not buy additional shares or sell existing shares. View analyst ratings for Cronos Group or view top-rated stocks. What is Cronos Group's stock price forecast for 2022? 8 analysts have issued 1 year price targets for Cronos Group's stock. Their CRON stock forecasts range from $3.00 to $6.00. On average, they predict Cronos Group's share price to reach $4.37 in the next year. This suggests a possible upside of 55.1% from the stock's current price. View analysts' price targets for Cronos Group or view top-rated stocks among Wall Street analysts. How has Cronos Group's stock price performed in 2022? Cronos Group's stock was trading at $3.92 at the start of the year. Since then, CRON shares have decreased by 28.1% and is now trading at $2.82. View the best growth stocks for 2022 here. When is Cronos Group's next earnings date? Cronos Group is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022. View our earnings forecast for Cronos Group. How were Cronos Group's earnings last quarter? Cronos Group Inc. (NASDAQ:CRON) issued its earnings results on Tuesday, May, 10th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.01. The firm earned $25.03 million during the quarter, compared to the consensus estimate of $30.66 million. Cronos Group had a negative net margin of 36.04% and a negative trailing twelve-month return on equity of 15.92%. The business's quarterly revenue was up 98.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.12) EPS. View Cronos Group's earnings history. Who are Cronos Group's key executives? Cronos Group's management team includes the following people: Mr. Michael Ryan Gorenstein J.D., Pres, CEO & Chairman (Age 35, Pay $389.15k) (LinkedIn Profile)Mr. Robert L. Madore, Chief Financial Officer (Age 57, Pay $164.42k)Ms. Shannon Buggy, Sr. VP & Global Head of People (Age 52, Pay $438.81k)Ms. Anna Shlimak, Sr. VP of Corp. Affairs & Strategy (Age 36, Pay $422.03k)Mr. Carlos Cortez, VP, Controller & Principal Accounting Officer (Age 49)Mr. Shayne J. Laidlaw, Director of Investor Relations & StrategyMr. Terry Gregory-Joseph Doucet, Sr. VP of Legal & Regulatory Affairs and Corp. Sec. (Age 32)Mr. Jeffrey David Jacobson, Sr. VP & Head of Growth of North America (Age 36)Mr. Arye Weigensberg, Interim Head of R&DMr. John Griese, Sr. VP & Head of Operations of North America (Age 60) Who are some of Cronos Group's key competitors? Some companies that are related to Cronos Group include Tilray (TLRY), USANA Health Sciences (USNA), Canopy Growth (CGC), Cresco Labs (CRLBF), Sundial Growers (SNDL), Canopy Rivers (RIV), True Drinks (TRUU), Bright Green (BGXX), Ayr Wellness (AYRWF), Ascend Wellness (AAWH), Aurora Cannabis (ACB), Mind Medicine (MindMed) (MNMD), MariMed (MRMD), biote (BTMD) and Exactus (EXDI). View all of CRON's competitors. What other stocks do shareholders of Cronos Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cronos Group investors own include (CGC), Aurora Cannabis (ACB), Tilray (TLRY), (APHA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Dollar Tree (DLTR), Micron Technology (MU), Alibaba Group (BABA) and OrganiGram (OGI). What is Cronos Group's stock symbol? Cronos Group trades on the NASDAQ under the ticker symbol "CRON." How do I buy shares of Cronos Group? Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cronos Group's stock price today? One share of CRON stock can currently be purchased for approximately $2.82. How much money does Cronos Group make? Cronos Group (NASDAQ:CRON) has a market capitalization of $1.07 billion and generates $74.43 million in revenue each year. The company earns $-396.11 million in net income (profit) each year or ($0.090010) on an earnings per share basis. How many employees does Cronos Group have? Cronos Group employs 626 workers across the globe. How can I contact Cronos Group? Cronos Group's mailing address is 111 PETER STREET SUITE 300, TORONTO A6, M5V 2G9. The official website for Cronos Group is www.thecronosgroup.com. The company can be reached via phone at (416) 504-0004. This page (NASDAQ:CRON) was last updated on 7/1/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
